Q8BZ03
Gene name |
Prkd2 |
Protein name |
Serine/threonine-protein kinase D2 |
Names |
EC 2.7.11.13 , nPKC-D2 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:101540 |
EC number |
2.7.11.13: Protein-serine/threonine kinases |
Protein Class |
|
Descriptions
Autoinhibitory domains (AIDs)
Target domain |
552-808 (Protein kinase domain) |
Relief mechanism |
PTM |
Assay |
|
Accessory elements
695-717 (Activation loop from InterPro)
Target domain |
552-808 (Protein kinase domain) |
Relief mechanism |
|
Assay |
|
Autoinhibited structure
Activated structure
1 structures for Q8BZ03
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q8BZ03-F1 | Predicted | AlphaFoldDB |
34 variants for Q8BZ03
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388855902 | 25 | G>S | No | EVA | |
| rs3397486358 | 27 | D>E | No | EVA | |
| rs3413084287 | 30 | S>* | No | EVA | |
| rs3388879730 | 47 | F>Y | No | EVA | |
| rs3388882873 | 82 | P>S | No | EVA | |
| rs3388862350 | 94 | L>M | No | EVA | |
| rs3397402297 | 109 | V>M | No | EVA | |
| rs3397708021 | 111 | S>P | No | EVA | |
| rs3388882341 | 203 | S>N | No | EVA | |
| rs240713316 | 310 | R>H | No | EVA | |
| rs244959058 | 326 | P>Q | No | EVA | |
| rs3388885394 | 332 | D>V | No | EVA | |
| rs3388882424 | 335 | E>A | No | EVA | |
| rs3388874002 | 353 | G>D | No | EVA | |
| rs214211872 | 358 | S>N | No | EVA | |
| rs3388879531 | 458 | L>R | No | EVA | |
| rs3388885917 | 462 | G>D | No | EVA | |
| rs3388862387 | 481 | E>G | No | EVA | |
| rs3388870238 | 485 | G>R | No | EVA | |
| rs3388870209 | 487 | P>R | No | EVA | |
| rs3388866096 | 492 | G>R | No | EVA | |
| rs3545452148 | 521 | P>L | No | EVA | |
| rs3388885023 | 525 | P>T | No | EVA | |
| rs3388879578 | 557 | V>M | No | EVA | |
| rs3388870217 | 562 | Q>* | No | EVA | |
| rs3397249224 | 571 | H>Y | No | EVA | |
| rs3388855865 | 585 | K>T | No | EVA | |
| rs3388882394 | 622 | E>* | No | EVA | |
| rs3388885930 | 649 | E>K | No | EVA | |
| rs3413068927 | 688 | P>S | No | EVA | |
| rs3388870297 | 691 | Q>* | No | EVA | |
| rs3388870239 | 701 | R>H | No | EVA | |
| rs3397709521 | 843 | A>T | No | EVA | |
| rs3388882843 | 865 | M>K | No | EVA |
No associated diseases with Q8BZ03
3 regional properties for Q8BZ03
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Toll/interleukin-1 receptor homology (TIR) domain | 837 - 981 | IPR000157 |
| domain | Sterile alpha motif domain | 687 - 754 | IPR001660-1 |
| domain | Sterile alpha motif domain | 757 - 826 | IPR001660-2 |
Functions
| Description | ||
|---|---|---|
| EC Number | 2.7.11.13 | Protein-serine/threonine kinases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
4 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| Golgi apparatus | A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
6 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| diacylglycerol-dependent serine/threonine kinase activity | Catalysis of the reaction |
| metal ion binding | Binding to a metal ion. |
| protein kinase C binding | Binding to protein kinase C. |
| protein serine kinase activity | Catalysis of the reactions |
| protein serine/threonine kinase activity | Catalysis of the reactions |
24 GO annotations of biological process
| Name | Definition |
|---|---|
| adaptive immune response | An immune response mediated by cells expressing specific receptors for antigens produced through a somatic diversification process, and allowing for an enhanced secondary response to subsequent exposures to the same antigen (immunological memory). |
| angiogenesis | Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels. |
| cell adhesion | The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules. |
| intracellular signal transduction | The process in which a signal is passed on to downstream components within the cell, which become activated themselves to further propagate the signal and finally trigger a change in the function or state of the cell. |
| phospholipase C-activating G protein-coupled receptor signaling pathway | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of phospholipase C (PLC) and a subsequent increase in the intracellular concentration of inositol trisphosphate (IP3) and diacylglycerol (DAG). |
| phosphorylation | The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide. |
| positive regulation of angiogenesis | Any process that activates or increases angiogenesis. |
| positive regulation of blood vessel endothelial cell migration | Any process that activates or increases the frequency, rate or extent of the migration of the endothelial cells of blood vessels. |
| positive regulation of cell adhesion | Any process that activates or increases the frequency, rate or extent of cell adhesion. |
| positive regulation of DNA biosynthetic process | Any process that activates or increases the frequency, rate or extent of DNA biosynthetic process. |
| positive regulation of DNA-binding transcription factor activity | Any process that activates or increases the frequency, rate or extent of activity of a transcription factor, any factor involved in the initiation or regulation of transcription. |
| positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway | The series of molecular signals initiated by the binding of a vascular endothelial growth factor (VEGF) to its receptor on the surface of a cell, which activates or increases the frequency, rate or extent of endothelial cell chemotaxis. |
| positive regulation of endothelial cell migration | Any process that increases the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium. |
| positive regulation of endothelial cell proliferation | Any process that activates or increases the rate or extent of endothelial cell proliferation. |
| positive regulation of ERK1 and ERK2 cascade | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. |
| positive regulation of fibroblast growth factor receptor signaling pathway | Any process that activates or increases the frequency, rate or extent of fibroblast growth factor receptor signaling pathway activity. |
| positive regulation of interleukin-2 production | Any process that activates or increases the frequency, rate, or extent of interleukin-2 production. |
| positive regulation of interleukin-8 production | Any process that activates or increases the frequency, rate, or extent of interleukin-8 production. |
| positive regulation of NF-kappaB transcription factor activity | Any process that activates or increases the frequency, rate or extent of activity of the transcription factor NF-kappaB. |
| positive regulation of T cell receptor signaling pathway | Any process that activates or increases the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a T cell. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| positive regulation of vascular endothelial growth factor receptor signaling pathway | Any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity. |
| regulation of T cell apoptotic process | Any process that modulates the occurrence or rate of T cell death by apoptotic process. |
| T cell receptor signaling pathway | The series of molecular signals initiated by the cross-linking of an antigen receptor on a T cell. |
8 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| O94806 | PRKD3 | Serine/threonine-protein kinase D3 | Homo sapiens (Human) | SS |
| Q15139 | PRKD1 | Serine/threonine-protein kinase D1 | Homo sapiens (Human) | EV |
| Q9BZL6 | PRKD2 | Serine/threonine-protein kinase D2 | Homo sapiens (Human) | SS |
| Q62101 | Prkd1 | Serine/threonine-protein kinase D1 | Mus musculus (Mouse) | SS |
| Q8K1Y2 | Prkd3 | Serine/threonine-protein kinase D3 | Mus musculus (Mouse) | SS |
| Q9WTQ1 | Prkd1 | Serine/threonine-protein kinase D1 | Rattus norvegicus (Rat) | SS |
| Q5XIS9 | Prkd2 | Serine/threonine-protein kinase D2 | Rattus norvegicus (Rat) | SS |
| O45818 | dkf-2 | Serine/threonine-protein kinase dkf-2 | Caenorhabditis elegans | SS |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAAAPSHPAG | LPGSPGPGSP | PPPGGLDLQS | PPPLLPQIPA | PGSGVSFHIQ | IGLTREFVLL |
| 70 | 80 | 90 | 100 | 110 | 120 |
| PAASELAHVK | QLACSIVDQK | FPECGFYGLY | DKILLFKHDP | TSANLLQLVR | SAADIQEGDL |
| 130 | 140 | 150 | 160 | 170 | 180 |
| VEVVLSASAT | FEDFQIRPHA | LTVHSYRAPA | FCDHCGEMLF | GLVRQGLKCD | GCGLNYHKRC |
| 190 | 200 | 210 | 220 | 230 | 240 |
| AFSIPNNCSG | ARKRRLSSTS | LASGHSVRLG | SSESLPCTAE | ELSRSTTDLL | PRRPPSSSSS |
| 250 | 260 | 270 | 280 | 290 | 300 |
| SSSSSFYTGR | PIELDKMLMS | KVKVPHTFLI | HSYTRPTVCQ | ACKKLLKGLF | RQGLQCKDCK |
| 310 | 320 | 330 | 340 | 350 | 360 |
| FNCHKRCATR | VPNDCLGEAL | INGDVPMEEA | ADYSEADKSS | ISDELEDSGV | IPGSHSESAL |
| 370 | 380 | 390 | 400 | 410 | 420 |
| HASEEEEGEG | HKAQSSLGYI | PLMRVVQSVR | HTTRKSSTTL | REGWVVHYSN | KDTLRKRHYW |
| 430 | 440 | 450 | 460 | 470 | 480 |
| RLDCKCITLF | QNNTTNRYYK | EIPLSEILAV | EPAQNFSLVP | PGTNPHCFEI | ITANVTYFVG |
| 490 | 500 | 510 | 520 | 530 | 540 |
| ETPGGAPGGP | SGQGTEAVRG | WETAIRQALM | PVILQDAPSA | PGHTPHRQAS | LSISVSNSQI |
| 550 | 560 | 570 | 580 | 590 | 600 |
| QENVDIATVY | QIFPDEVLGS | GQFGVVYGGK | HRKTGRDVAV | KVIDKLRFPT | KQESQLRNEV |
| 610 | 620 | 630 | 640 | 650 | 660 |
| AILQSLRHPG | IVNLECMFET | PEKVFVVMEK | LHGDMLEMIL | SSEKGRLPER | LTKFLITQIL |
| 670 | 680 | 690 | 700 | 710 | 720 |
| VALRHLHFKN | IVHCDLKPEN | VLLASADPFP | QVKLCDFGFA | RIIGEKSFRR | SVVGTPAYLA |
| 730 | 740 | 750 | 760 | 770 | 780 |
| PEVLLNQGYN | RSLDMWSVGV | IMYVSLSGTF | PFNEDEDIND | QIQNAAFMYP | ASPWSHISSG |
| 790 | 800 | 810 | 820 | 830 | 840 |
| AIDLINNLLQ | VKMRKRYSVD | KSLSHPWLQE | YQTWLDLREL | EGKMGERYIT | HESDDARWDQ |
| 850 | 860 | 870 | |||
| FVAERHGTPA | EGDLGGACLP | QDHEMQGLAE | RISIL |